Literature DB >> 29296543

IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Clément Barjon1, Henri-Alexandre Michaud1, Angeline Fages1, Cécile Dejou2, Alexandre Zampieri1, Laetitia They1, Aurélie Gennetier1, Françoise Sanchez1, Laurent Gros1, Jean-François Eliaou1,2,3, Nathalie Bonnefoy1, Virginie Lafont1,3.   

Abstract

Vγ9Vδ2 T cells contribute to the immune response against many tumor types through their direct cytotoxic activity and capacity to regulate the biological functions of other immune cells, such as dendritic cells and IFN-γ-producing CD8+ T cells. However, their presence in the tumor microenvironment has also been associated with poor prognosis in breast, colon and pancreatic cancers. Additionally, recent studies demonstrated that cytokines can confer some plasticity to Vγ9Vδ2 T cells and promote their differentiation into cells with regulatory functions. Here, we demonstrated that activation of Vγ9Vδ2 T cells isolated from healthy donors and cultured in the presence of IL-21 favors the emergence of a subpopulation of Vγ9Vδ2 T cells that express the ectonucleotidase CD73 and inhibits T cell proliferation in a CD73/adenosine-dependent manner. This subpopulation produces IL-10 and IL-8 and displays lower effector functions and cytotoxic activity than CD73-negative Vγ9Vδ2 T cells. We also showed, in a syngeneic mouse tumor model, the existence of a tumor-infiltrating γδ T cell subpopulation that produces IL-10 and strongly expresses CD73. Moreover, maturation, IL-12 production and induction of antigen-specific T cell proliferation are impaired in DC co-cultured with IL-21-amplified Vγ9Vδ2 T cells. Altogether, these data indicate that IL-21 promotes Vγ9Vδ2 T cell regulatory functions by favoring the development of an immunosuppressive CD73+ subpopulation. Thus, when present in the tumor microenvironment, IL-21 might negatively impact γδ T cell anti-tumor functions.

Entities:  

Keywords:  CD73; IL-10; IL-21; adenosine; regulatory functions; tumor microenvironment; γδ T cells

Year:  2017        PMID: 29296543      PMCID: PMC5739578          DOI: 10.1080/2162402X.2017.1379642

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  42 in total

1.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells.

Authors:  Massimo C Fantini; Agelamaria Rizzo; Daniele Fina; Roberta Caruso; Christoph Becker; Markus F Neurath; Thomas T Macdonald; Francesco Pallone; Giovanni Monteleone
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

3.  Tumor-infiltrating CD39+γδTregs are novel immunosuppressive T cells in human colorectal cancer.

Authors:  Guoming Hu; Pin Wu; Pu Cheng; Zhigang Zhang; Zhen Wang; Xiuyan Yu; Xuan Shao; Dang Wu; Jun Ye; Tao Zhang; Xiaochen Wang; Fuming Qiu; Jun Yan; Jian Huang
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

4.  Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Authors:  Jeremy Bastid; Anne Regairaz; Nathalie Bonnefoy; Cécile Déjou; Jérôme Giustiniani; Caroline Laheurte; Stéphanie Cochaud; Emilie Laprevotte; Elisa Funck-Brentano; Patrice Hemon; Laurent Gros; Nicole Bec; Christian Larroque; Gilles Alberici; Armand Bensussan; Jean-François Eliaou
Journal:  Cancer Immunol Res       Date:  2014-11-17       Impact factor: 11.151

Review 5.  [Tgammadelta lymphocytes in oncology: unconventional killer lymphocytes].

Authors:  Véronique Catros; Olivier Toutirais; Françoise Bouet; Florian Cabillic; Mireille Desille; Jean-Jacques Fournié
Journal:  Med Sci (Paris)       Date:  2010-02       Impact factor: 0.818

Review 6.  The role of IL-21 in hematological malignancies.

Authors:  Jingjing Ma; Daoxin Ma; Chunyan Ji
Journal:  Cytokine       Date:  2011-08-06       Impact factor: 3.861

Review 7.  ENTPD1/CD39 is a promising therapeutic target in oncology.

Authors:  J Bastid; A Cottalorda-Regairaz; G Alberici; N Bonnefoy; J-F Eliaou; A Bensussan
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

8.  Ecto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens.

Authors:  Georg Gruenbacher; Hubert Gander; Andrea Rahm; Marco Idzko; Oliver Nussbaumer; Martin Thurnher
Journal:  Cell Rep       Date:  2016-06-23       Impact factor: 9.423

9.  Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway.

Authors:  Guangyong Peng; Helen Y Wang; Weiyi Peng; Yukiko Kiniwa; Kook Heon Seo; Rong-Fu Wang
Journal:  Immunity       Date:  2007-07-26       Impact factor: 31.745

10.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.

Authors:  Rong Zeng; Rosanne Spolski; Steven E Finkelstein; SangKon Oh; Panu E Kovanen; Christian S Hinrichs; Cynthia A Pise-Masison; Michael F Radonovich; John N Brady; Nicholas P Restifo; Jay A Berzofsky; Warren J Leonard
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

View more
  11 in total

Review 1.  Regulatory functions of γδ T cells.

Authors:  Christian Peters; Dieter Kabelitz; Daniela Wesch
Journal:  Cell Mol Life Sci       Date:  2018-03-08       Impact factor: 9.261

Review 2.  Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors:  Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

Review 3.  Targeting Cytokine Signals to Enhance γδT Cell-Based Cancer Immunotherapy.

Authors:  Yuan Song; Yonghao Liu; Huey Yee Teo; Haiyan Liu
Journal:  Front Immunol       Date:  2022-06-07       Impact factor: 8.786

4.  Diversity of Tumor-Infiltrating, γδ T-Cell Abundance in Solid Cancers.

Authors:  Ghita Chabab; Florence Boissière-Michot; Caroline Mollevi; Jeanne Ramos; Evelyne Lopez-Crapez; Pierre-Emmanuel Colombo; William Jacot; Nathalie Bonnefoy; Virginie Lafont
Journal:  Cells       Date:  2020-06-24       Impact factor: 6.600

5.  Influence of Indoleamine-2,3-Dioxygenase and Its Metabolite Kynurenine on γδ T Cell Cytotoxicity against Ductal Pancreatic Adenocarcinoma Cells.

Authors:  Hannah Jonescheit; Hans-Heinrich Oberg; Daniel Gonnermann; Martin Hermes; Vjola Sulaj; Christian Peters; Dieter Kabelitz; Daniela Wesch
Journal:  Cells       Date:  2020-05-06       Impact factor: 6.600

6.  Characterization of Donor Variability for γδ T Cell ex vivo Expansion and Development of an Allogeneic γδ T Cell Immunotherapy.

Authors:  Rebecca E Burnham; Jaquelyn T Zoine; Jamie Y Story; Swetha N Garimalla; Greg Gibson; Aaron Rae; Erich Williams; Lisa Bixby; David Archer; Christopher B Doering; H Trent Spencer
Journal:  Front Med (Lausanne)       Date:  2020-11-13

Review 7.  Pro-tumor γδ T Cells in Human Cancer: Polarization, Mechanisms of Action, and Implications for Therapy.

Authors:  Ghita Chabab; Clément Barjon; Nathalie Bonnefoy; Virginie Lafont
Journal:  Front Immunol       Date:  2020-09-16       Impact factor: 7.561

8.  MEGF11 is related to tumour recurrence in triple negative breast cancer via chemokine upregulation.

Authors:  Jen-Hwey Chiu; Ling-Ming Tseng; Tzu-Ting Huang; Chun-Yu Liu; Jir-You Wang; Ching-Po Huang; Yi-Fang Tsai; Chih-Yi Hsu
Journal:  Sci Rep       Date:  2020-05-15       Impact factor: 4.379

Review 9.  Vγ9Vδ2 T Cells in the Bone Marrow of Myeloma Patients: A Paradigm of Microenvironment-Induced Immune Suppression.

Authors:  Barbara Castella; Myriam Foglietta; Chiara Riganti; Massimo Massaia
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

Review 10.  Natural killer cells in cancer biology and therapy.

Authors:  Song-Yang Wu; Tong Fu; Yi-Zhou Jiang; Zhi-Ming Shao
Journal:  Mol Cancer       Date:  2020-08-06       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.